CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...
Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback